About SeQure Dx
SeQure Dx is a company based in Waltham (United States) founded in 2020 by Ellen Sheets was acquired by MaxCyte in January 2025. SeQure Dx has raised $22.29 million across 3 funding rounds from investors including MaxCyte, ARE and RiverVest Venture Partners. SeQure Dx offers products and services including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System. SeQure Dx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Waltham, United States
- Founders Ellen Sheets
- SectorsHealthcare
- Email••••••••
- Website sequre-dx.com
- Social LinkedIn
- Acquired by MaxCyte (Jan 2025)
Products & Services of SeQure Dx
SeQure Dx offers a comprehensive portfolio of products and services, including ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and ATx System.
Variant-aware guide selection for therapeutic gene editing.
Efficient interrogation of DNA rearrangements in edited cells.
Computational aid for improved guide RNA selection in CRISPR.
Systems for cell transfection in therapy production.
Device for small to medium static electroporation processes.
Scalable electroporation for up to 20 billion cells.
Clinically validated flow-through electroporation device.
Tool for gram-scale protein production via electroporation.
Funding Insights of SeQure Dx
SeQure Dx has successfully raised a total of $22.29M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.18 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.29M
- Total Rounds 3
- Last Round Series A — $2.18M
- First Round $17.5M
(Aug 2021)
- Investors Count 7
All 3 funding rounds of SeQure Dx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $2.18M | Series A | – | – | – |
| Jun 2023 | $2.61M | Series A | – | – | – |
| Aug 2021 | $17.5M | Series A | – | RiverVest Venture Partners, Mass General Brigham Ventures |
8 investors in total: 8 institutional.
Investors in SeQure Dx
SeQure Dx has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MaxCyte, ARE and RiverVest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | rivervest.com | - | |
- | – | massgeneralbrighamventures.com | - | |
Digitalis Ventures is engaged in health-focused investments. | – | digitalisventures.com | New York, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Early-stage investments are made in frontier science ventures. | – | kdtvc.com | Black Mountain, United States | |
Early-stage life sciences and tech focused VC firm investing primarily in the US | – | boldcapitalpartners.com | Santa Monica, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Instrument systems for cell processing and modification are provided. | 1998 | maxcyte.com | Gaithersburg, United States |
Investor details for SeQure Dx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SeQure Dx
6 people are tracked at SeQure Dx (5 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Ellen Sheets | Founder | Leadership |
Marc C. | Associate Director - Facilities and Lab Operation | Leadership |
Sophia Oladimeji MBA PMP | Senior Director Program and Portfolio Management | Leadership |
Andrew Hollinger | VP Product & Marketing - Life Sciences │ OTE │ Product Strategist | Leadership |
Joe Mohr | Senior Director, Business Development | Leadership |
Ricardo Petroni, PhD | Senior Scientist R&D | Team |
Complete people profiles for SeQure Dx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SeQure Dx
4 dated milestones of SeQure Dx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded SeQure Dx is founded.
- Funding First funding round of $17.5M.
- Funding Latest funding round, Series A, of $2.2M.
- Exit Acquired by MaxCyte.
Competitors of SeQure Dx
SeQure Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of SeQure Dx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sequre Dx
Complete news archive for SeQure Dx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SeQure Dx
10 companies that operate in the same segment as SeQure Dx (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SeQure Dx
SeQure Dx was founded in 2020 and raised its 1st funding round 1 year after it was founded.
SeQure Dx is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
SeQure Dx is a funded company, having raised a total of $22.29M across 3 funding rounds to date. The company's 1st funding round was a Series A of $17.5M, raised on Aug 2021.
Developer of personalized diagnostics for gene-editing therapies. The companys technologies GUIDE-seq and ONE-seq enable the identification and confirmation of target sites for developing gene therapies.
SeQure Dx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
SeQure Dx offers ONE-seq, SAFER Detection, Guide Profiler, Electroporation Systems, and 4 more products and services.
SeQure Dx has 8 investors. Key investors include MaxCyte, ARE, RiverVest Venture Partners, Mass General Brigham Ventures, and Digitalis Ventures.
Yes. SeQure Dx was acquired by MaxCyte in January 2025.